PDGFRB — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1522	1.00	12/20
SCHEMBL1430	0.88	12/20
SCHEMBL9565	1.00	11/20
SCHEMBL9642	1.00	11/20
SCHEMBL9763	1.00	11/20
SCHEMBL10208	0.82	11/20
SCHEMBL9838	0.79	11/20
SCHEMBL9971	0.57	11/20
Bilirubin (SCHEMBL19065)	0.38	11/20
SCHEMBL9197	1.00	10/20
SCHEMBL9862	0.79	10/20
SCHEMBL1442	0.78	10/20
SCHEMBL1365	1.00	9/20
SCHEMBL1762	1.00	9/20
SCHEMBL9338	1.00	9/20
Vatalanib (SCHEMBL18286)	1.00	9/20
SCHEMBL9469	0.76	9/20
SCHEMBL9519	0.67	9/20
SCHEMBL9588	1.00	8/20
SCHEMBL9782	1.00	8/20

Clinical trials — most relevant to PDGFRB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Platelet Rich Plasma in Corneal Surface Diseases	PHASE3	UNKNOWN
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	PHASE2	COMPLETED
Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients	PHASE2	COMPLETED
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients	PHASE2	ENROLLING_BY_INVITATION
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab	PHASE2	COMPLETED
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations	PHASE2	WITHDRAWN
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy	PHASE2	COMPLETED
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer	PHASE2	COMPLETED
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma	PHASE2	COMPLETED
Effect of Imatinib in Advance Liver Fibrosis Patients	PHASE1/PHASE2	UNKNOWN
Treatment of Corneal Neovascularization With Topical Pazopanib	PHASE1/PHASE2	COMPLETED
Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma	PHASE2	UNKNOWN
First-line Therapy of Stage IV Colorectal Cancer	PHASE1/PHASE2	COMPLETED
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors	PHASE1	WITHDRAWN
89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma	PHASE1	RECRUITING
Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration	PHASE1	COMPLETED
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)	PHASE1	ACTIVE_NOT_RECRUITING
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function	PHASE1	COMPLETED
Platelet-Rich Plasma for Partial Rotator Cuff Tears	nan	NOT_YET_RECRUITING
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion	nan	ACTIVE_NOT_RECRUITING
Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia	nan	UNKNOWN
Management of Retinitis Pigmentosa Via Electromagnetic Stimulation and Platelet Rich Plasma	nan	COMPLETED
Platelet Rich Plasma for Treatment of Facial Photoaging: A Double-blind, Randomized, Split-face Study	nan	UNKNOWN
PRP Versus PRF Versus Conventional Treatment in Chronic Non-healing Skin Ulcers	nan	RECRUITING
Efficacy of Platelet-Rich Plasma Therapy for Androgenetic Alopecia: A Systematic Review and Meta-analysis	nan	UNKNOWN
Combined LASERs and PRP for Postacne Scars	nan	COMPLETED
Platelet Rich Plasma Versus Placebo for the Treatment of Greater Trochanteric Pain Syndrome (HiPPO Trial)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PDGFRB binder may also engage these)

Protein	Name	Similarity
Q6QNF3	—	1.000	Q6QNF3 →
Q00495	—	1.000	Q00495 →
P05622	—	0.999	P05622 →
Q8JFR5	—	0.997	Q8JFR5 →
Q8AXC7	—	0.997	Q8AXC7 →
CSF1R	Macrophage colony-stimulating factor 1 receptor	0.997	landscape →
Q05030	—	0.997	Q05030 →
P26619	—	0.996	P26619 →
Q9I8N6	—	0.996	Q9I8N6 →
P09581	—	0.996	P09581 →
P13369	—	0.996	P13369 →
P79749	—	0.995	P79749 →
P35546	—	0.995	P35546 →
Q28889	—	0.995	Q28889 →
P79750	—	0.994	P79750 →
P43481	—	0.994	P43481 →
Q8UVR8	—	0.994	Q8UVR8 →
P52583	—	0.994	P52583 →
Q2HWD6	—	0.993	Q2HWD6 →
Q9PUF6	—	0.993	Q9PUF6 →
Q91909	—	0.993	Q91909 →
P26618	—	0.993	P26618 →
Q5GIT4	—	0.993	Q5GIT4 →
Q28317	—	0.993	Q28317 →
Q76II0	—	0.993	Q76II0 →
Q9DE49	—	0.993	Q9DE49 →
B6ZK77	—	0.993	B6ZK77 →
Q08156	—	0.992	Q08156 →
PDGFRA	Platelet-derived growth factor receptor alpha	0.992	landscape →
Q8AXC6	—	0.992	Q8AXC6 →